# Newlife Capital

> Newlife Capital is a VC fund in Beijing backing Biotechnology and Medical. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 6
- Last investment: Apr 2026
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/nrlcapital/
- Website: https://www.nrl-capital.cn/

Newlife Capital is a VC fund in Beijing focused on Biotechnology and Medical. Newley Capital is an investment and fund management platform that leverages top domestic and international industry resources and long-term capital. It operates across fund of funds, direct investment, and private equity secondary share investments, utilizing both domestic RMB and overseas US dollars. The platform focuses on sectors likehealthcare, semiconductors and intelligent manufacturing, new energy and carbon neutrality, and consumer technology.

## Contacts

5 contacts available for Newlife Capital. Shizune tracks 2 team members at Newlife Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/newlife-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 33% |
| Medical | 1 | 17% |
| Data Center | 1 | 17% |
| Health Care | 1 | 17% |
| Therapeutics | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 33% |
| Series A | 2 | 33% |
| Series B | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 3 | 50% |
| United States | 2 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Deng Shuang | Founding Partner | 0 | — |
| Lin Xianghong | Founding Partner | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aureka Biotechnologies | Aureka Biotechnologies is a pioneering biotech firm dedicated to democratizing the pharmaceutical sector in order to conquer sickness. | $35M | Series A | Apr 28, 2026 |  |
| Yipuji | Yipuji provides modular data center infrastructure products and integrated engineering services that support the planning, design, prefabrication, and deployment of scalable data center facilities. The company’s portfolio includes prefabricated (modular) data center solutions such as all-in-one systems, flatpack edge modules, liquid-cooling modulestailored for high-performance computing, and functional modular components that help streamline construction workflows. It combines research, development, manufacturing, and technical service capabilities to deliver standardized yet customizable modules that aim to shorten build cycles and support technical teams in meeting project specifications. Yipuji also engages in product innovation and collaborates with technology partners to develop solutions for emerging needs like AI data centers and energy-efficient thermal management. The business integrates prefabrication with on-site delivery coordination, technical support resources, and engineering services to assist customers from design through implementation. Its activities include engineering research, ongoing technical support, and collaborations with academic and industry organizations to advance modular data center technologies. | $100M | Series B | Jan 23, 2026 |  |
| Revelyx | Revelyx Bio is a clinical-stage biotechnology business that specializes in novel botulinum toxin therapies. |  | Series A | Jan 09, 2026 |  |
| Inruidi | Inruidi is a medical technology service provider specializing in the sales of high-quality medical devices and the provision of comprehensive technical services. With a strong commitment to innovation and customer support, the company offers tailored solutions to healthcare institutions, ensuring reliable performance, regulatory compliance, andoptimal integration of advanced medical technologies into clinical practice. |  | Seed | Oct 16, 2025 |  |
| Aureka Biotechnologies | Aureka Biotechnologies is a pioneering biotech firm dedicated to democratizing the pharmaceutical sector in order to conquer sickness. | $23.4M | Series A | Sep 26, 2025 |  |
| Jinling Biopharma | Jinling Bio is a company specializing in medical research and experimental development, focusing on medical technology innovation and related services. |  | Seed | Sep 08, 2025 |  |

6 of 6 investments shown.

## Co-investors
- [5Y Capital](https://shizune.co/investors/profile/morningsidevc) — VC Fund, 2 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 1 deal together
- [Forebright Capital](https://shizune.co/investors/profile/forebright-capital) — VC Fund, 1 deal together
- [GL Ventures LLC](https://shizune.co/investors/profile/gl-ventures-llc) — VC Fund, 1 deal together
- InnoPinnacle Fund — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Newlife Capital invest in?

Newlife Capital invests primarily in Biotechnology, Medical and Data Center startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Newlife Capital?

Public channels for Newlife Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Newlife Capital?

The team at Newlife Capital includes Deng Shuang (Founding Partner) and Lin Xianghong (Founding Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co